PTP4A3 and neoplasm: Finally, a specific PRL-3 binding antibody has been developed, which is currently the only inhibitor capable of selectively targeting PRL-3 over other family members and is capable of preventing tumor growth using in vivo model of both hepatic and gastric cancers16,44.